Compare TPL & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TPL | PODD |
|---|---|---|
| Founded | 1888 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6B | 22.1B |
| IPO Year | N/A | 2007 |
| Metric | TPL | PODD |
|---|---|---|
| Price | $296.27 | $284.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 19 |
| Target Price | $350.00 | ★ $366.58 |
| AVG Volume (30 Days) | 452.8K | ★ 631.2K |
| Earning Date | 02-18-2026 | 02-19-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | ★ 6.20 | N/A |
| EPS | ★ 6.90 | 3.45 |
| Revenue | $772,395,000.00 | ★ $2,521,800,000.00 |
| Revenue This Year | $10.07 | $32.55 |
| Revenue Next Year | $19.21 | $20.50 |
| P/E Ratio | ★ $43.18 | $81.99 |
| Revenue Growth | 12.48 | ★ 27.11 |
| 52 Week Low | $269.23 | $230.05 |
| 52 Week High | $487.59 | $354.88 |
| Indicator | TPL | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 17.16 | 35.69 |
| Support Level | $280.95 | $285.02 |
| Resistance Level | $298.00 | $290.60 |
| Average True Range (ATR) | 20.39 | 5.78 |
| MACD | -43.33 | 0.27 |
| Stochastic Oscillator | 2.50 | 27.29 |
Texas Pacific Land Corp is mainly engaged in the sales and leases of land owned, retaining oil and gas royalties, and the overall management of the land owned. It operates its business in two reportable segments; Land and Resource Management and Water Service and Operations. The Land and Resource Management segment focuses on managing surface acres of land and its oil and gas royalty interests, principally concentrated in the Permian Basin. The Water Services and Operations segment encompasses the business of providing full-service water offerings to operators, produced-water treatment, infrastructure development, and disposal solutions. The company generates the majority of its revenue from the Land and Resource Management segment.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.